ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
57,961.49
-4.35%
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs Yen
155.1675
-1.62%
Brent Oil
83.54
-2.74%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) ニュース

ESPR Esperion Therapeutics Inc

2.08
0.11 (5.58%)
取引時間後
最終更新日： 07:31:13
15分遅延
名称 銘柄コード 市場 種別
Esperion Therapeutics Inc ESPR NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
Upgrade Icon
0.11 5.58% 2.08 07:31:13
始値 安値 高値 終値 前日終値
1.99 1.94 2.12 2.04 1.97
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/2921:00GLOBEEsperion to Participate in Upcoming May Investor Conferences
2024/4/2321:00GLOBEEsperion to Report First Quarter 2024 Financial Results on..
2024/4/0803:45GLOBEEsperion Presents Important New Data from CLEAR Outcomes at..
2024/4/0121:00GLOBEEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024
2024/3/2621:00GLOBEEsperion to Participate in 23rd Annual Needham Virtual..
2024/3/2605:00GLOBEEsperion Announces Data from CLEAR Outcomes Sub-Groups as..
2024/3/2307:26BWU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL®..
2024/3/2304:10GLOBEU.S. FDA Approves Broad New Labels for NEXLETOL® and..
2024/3/2300:04GLOBECHMP Issues Positive Opinions For Both Bempedoic Acid And..
2024/2/2723:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2024/2/2721:23EDGAR2Form 8-K - Current report
2024/2/2720:00GLOBEEsperion Reports Fourth Quarter and Full Year 2023 Financial..
2024/2/1706:30GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
2024/2/1504:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1500:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1422:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1420:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2024/2/1322:00GLOBEEsperion to Report Fourth Quarter and Full Year 2023..
2024/2/0204:00GLOBERFK, Esperion Therapeutics Announce 2024 Promotional..
2024/1/2406:00GLOBEEsperion Announces Closing of Public Offering of Common..
2024/1/2220:10EDGAR2Form 8-K - Current report
2024/1/2220:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/1/1911:15GLOBEEsperion Announces Pricing of $85.1 Million Public Offering..
2024/1/1906:03EDGAR2Form 8-K - Current report
2024/1/1906:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
2024/1/1906:00GLOBEEsperion Announces Proposed Public Offering of Common Stock
2024/1/1206:09EDGAR2Form 8-K - Current report
2024/1/0405:15BWEsperion e Daiichi Sankyo Europe annunciano un emendamento..
2024/1/0403:54BWEsperion et Daiichi Sankyo Europe annoncent une révision de..
2024/1/0400:07BWEsperion und Daiichi Sankyo Europe geben Anpassung ihrer..
2024/1/0322:00EDGAR2Form 8-K - Current report
2024/1/0321:00GLOBEEsperion and Daiichi Sankyo Europe Announce $125 Million..
2023/12/1822:00GLOBEEsperion to Participate in 42nd Annual J.P. Morgan..
2023/12/1406:46DJNEsperion Therapeutics' Nexletol, Nexlizet Updates Get FDA..
2023/12/1406:00GLOBEU.S. FDA Updates LDL-C Lowering Indication for Esperion’s..
2023/11/1400:30GLOBEEsperion Presents CLEAR Outcomes Analysis of Inflammation as..
2023/11/1201:00GLOBEPartners Announce TRANSFORM Trial to Evaluate Personalized..
2023/11/1006:30GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
2023/11/0722:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/0721:30EDGAR2Form 8-K - Current report
2023/11/0720:00GLOBEEsperion Reports Third Quarter 2023 Financial Results
2023/10/3121:00GLOBEEsperion to Participate in Jefferies London Healthcare..
2023/10/2421:00GLOBEEsperion to Report Third Quarter 2023 Financial Results on..
2023/10/0522:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
2023/9/2206:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/9/2104:22EDGAR2Form 144 - Report of proposed sale of securities
2023/9/1223:15GLOBEAmerican College of Cardiology Program to Increase..
2023/8/2821:00GLOBEEsperion to Participate in H.C. Wainwright 25th Annual..
2023/8/2700:00GLOBEEsperion Presents Two CLEAR Outcomes Study Late-Breakers at..
2023/8/2422:29EDGAR2Form S-8 - Securities to be offered to employees in employee..

最近閲覧した銘柄

NASDAQ
ESPR
Esperion Therapeutics
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有